VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Q1 2025 Earnings Call Transcript
Operator: Ladies and gentlemen, greetings and welcome to Vistagen Therapeutics Fiscal Year 2025 First Quarter Corporate Update Conference Call.
No. | Hedge Fund | Shares | Value | Activity | % Port |
---|---|---|---|---|---|
1. | Biotechnology Value Fund / BVF Inc Mark Lampert | 2,000,000 | $6,960,000 | 0.19% | |
2. | StemPoint Capital Michelle Ross | 1,848,582 | $5,848,164 | 1.71% | |
3. | Commodore Capital Egen Atkinson And Michael Kramarz | 1,575,000 | $5,481,000 | 0.37% | |
4. | Great Point Partners Jeffrey Jay And David Kroin | 1,529,338 | $5,322,096 | -18% | 1.01% |
5. | Nantahala Capital Management Wilmot B. Harkey And Daniel Mack | 1,517,696 | $5,281,582 | 0.3% |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$23.15 | 775,756 | Large Shareholder | 1,575,000 | 2023-08-07 | Filing | |
$0.18 | 100,000 | 100,000 | 2022-08-18 | Filing | ||
$0.18 | 100,000 | 100,000 | 2022-08-18 | Filing | ||
$0.17 | 300,000 | 334,629 | 2022-08-17 | Filing | ||
$0.17 | 600,000 | 626,234 | 2022-08-17 | Filing |
Insider | Price | Amount | Relationship | Remaining Holdings | Date | Form 4 |
---|---|---|---|---|---|---|
$0.89 | 60,000 | Large Shareholder | 20,637,286 | 2022-07-12 | Filing | |
$3.13 | 30,000 | 72,786 | 2021-09-07 | Filing | ||
$0.00 | 4,982,103 | 17,897 | 2011-05-09 | Filing |
No. | Name | Shares | Value | % Port |
---|---|---|---|---|
1. | 2,676,580 | $13,757,621 | 1.52% | |
2. | 1,834,512 | $9,429,391 | 0% | |
3. | 556,500 | $2,860,410 | 0% | |
4. | 346,683 | $1,781,951 | 0% | |
5. | 309,800 | $1,592,372 | 0% |